Facial Plast Surg 2009; 25(2): 100-105
DOI: 10.1055/s-0029-1220649
© Thieme Medical Publishers

Injectable Calcium Hydroxylapatite Microspheres (Radiesse)

Brock Ridenour1 , Theda C. Kontis2
  • 1Ridenour Plastic Surgery, St. Louis, Missouri
  • 2Assistant Professor, Johns Hopkins Medical Institutions, Baltimore, Maryland
Further Information

Publication History

Publication Date:
04 May 2009 (online)

ABSTRACT

Injectable calcium hydroxylapatite (Radiesse) received FDA approval in 2006 for the correction of facial lipoatrophy and moderate to severe facial wrinkles. This product consists of microspheres of a synthetic bone suspended in a methylcellulose gel matrix. Because the product is thicker than the hyaluronic acids, it is used for the correction of moderate to severe wrinkles, such as deep nasolabial folds. It is also used “off-label” to treat multiple areas of the face, nose, and hands. Radiesse is injected into the subdermal plane, and correction lasts approximately 1 year after injection.

REFERENCES

  • 1 Alam M, Gladstone H, Kramer E M et al.. (Guidelines Task Force). ASDS guidelines of care: injectable fillers.  Dermatol Surg. 2008;  34 S115-S148
  • 2 Berlin A L, Hussain M, Goldberg D J. Calcium hydroxylapatite filler for facial rejuvenation: a histologic and immunohistochemical analysis.  Dermatol Surg. 2008;  34 S64-S67
  • 3 Marmur E S, Phelps R, Goldberg D J. Clinical, histologic and electron microscopic findings after injection of a calcium hydroxylapatite filler.  J Cosmet Laser Ther. 2004;  6 223-226
  • 4 Coleman K M, Voigts R, Devore D P, Termin P, Coleman W P. Neocollagenesis after injection of calcium hydroxylapatite composition in a canine model.  Dermatol Surg. 2008;  34 S53-S55
  • 5 Carruthers A, Liebeskind M, Carruthers J, Forster B B. Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of human immunodeficiency virus-associated facial lipoatrophy and correction of nasolabial folds.  Dermatol Surg. 2008;  34 S78-S84
  • 6 Hevia O. A retrospective review of calcium hydroxylapatite for correction of volume loss in the infraorbital region.  Dermatol Surg. 2009;  , In press
  • 7 Becker H. Nasal augmentation with calcium hydroxylapatite in a carrier gel.  Plast Reconstr Surg. 2008;  121 2142-2147
  • 8 Stupak H D, Moulthrop T H, Wheatley P, Tauman A V, Johnson C M. Calcium hydroxylapatite gel (Radiesse) injection for the correction of postrhinoplasty contour deficiencies and asymmetries.  Arch Facial Plast Surg. 2007;  9 130-136
  • 9 Werschler W P. Treating the aging face: a multidisciplinary approach with calcium hydroxylapatite and other fillers, part 1.  J Cosmet Dermatol. 2007;  20 739-742
  • 10 Werschler W P. Treating the aging face: a multidisciplinary approach with calcium hydroxylapatite and other fillers, part 2.  J Cosmet Dermatol. 2007;  20 791-796
  • 11 Smith S, Busso M, McClaren M, Bass L S. A randomized, bilateral, prospective comparison of calcium hydroxylapatite microspheres versus human-based collagen for the correction of nasolabial folds.  Dermatol Surg. 2007;  33 S112-S121
  • 12 Bass L S, Smith S, Busso M, McClaren M. Calcium hydroxylapatite for treatment of nasolabial folds: long-term safety and efficacy results.  Aesthet Surg J. 2009;  , In press
  • 13 Graivier M H, Bass L S, Busso M, Jasin M E, Narins R S, Tzikas T L. Calcium hydroxylapatite (Radiesse) for correction of the mid- and lower face: consensus recommendations.  Plast Reconstr Surg. 2007;  120(Suppl) 55S-66S
  • 14 Silvers S L, Eviatar J E, Echavez M I, Pappas A L. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.  Plast Reconstr Surg. 2006;  118(Suppl) 34S-45S
  • 15 Busso M, Applebaum D. Hand augmentation with Radiesse (calcium hydroxylapatite).  Dermatol Ther. 2007;  20 385-387
  • 16 Nyte C P. Spreader graft injection with calcium hydroxylapatite: a nonsurgical technique for internal nasal valve collapse.  Laryngoscope. 2006;  116 1291-1292
  • 17 Moers-Carpi M, Tufet J O. Calcium hydroxylapatite versus nonanimal stabilized hyaluronic acid for the correction of nasolabial folds: a 12-month, multicenter, prospective, randomized, controlled, split-face trial.  Dermatol Surg. 2008;  34 210-215
  • 18 Moers-Carpi M, Vogt S, Santos B M, Planas J, Vallve S R, Howell D J. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds.  Dermatol Surg. 2007;  33 S144-S151
  • 19 Sadick N S, Katz B E, Roy D. A multicenter, 47-month study of safety and efficacy of calcium hydroxylapatite for soft tissue augmentation of nasolabial folds and other areas of the face.  Dermatol Surg. 2007;  33 S122-S127
  • 20 Tzikas T L. A 52-month summary of results using calcium hydroxylapatite for facial soft tissue augmentation.  Dermatol Surg. 2008;  34 S9-S15
  • 21 Marmur E S, Taylor S C, Grimes P E, Boyd C M. Calcium hydroxylapatite for treatment of nasolabial folds in Fitzpatrick skin types IV–VI. Poster presented at: Summer AAD July 31–August 2, 2008 Chicago, IL; [presentation 2501]

Brock RidenourM.D. F.A.C.S. 

Ridenour Plastic Surgery, 12460 Olive Blvd.

Suite 202, St. Louis, MO 63141

Email: Brock.ridenour@ridenourplasticsurgery.com